A new chemical compound for treating human inflammatory diseases, tissue damage, stroke, septic shock and cancer. This chemical compound is produced from a process including the following steps: (a) washing human foreskin fibroblasts with a fresh DMEM medium then incubated in a fresh medium containing 2.5%-10% fetal bovine serum for at least 8 hours to form a proliferating phase medium (PPM); (b) subjecting the proliferating phase medium to a 10-kDa ultrafiltration membrane to separate the proliferating phase medium into a 10 kDa fraction, which passes through the 10-kDa ultrafiltration membrane, and a 10 kDa fraction, which is retained by the 10-kDa ultrafiltration membrane; (c) Chromatographing the 10 kDa fraction on a Superdex 30 column by FPLC to separate the 10 kDa fraction into five post-FPLC fractions; (d) Injecting the second post-FPLC fraction into a C₁₈ column in a HPLC system with a gradient elute from 10% to 50% acetonitrile and water containing 0.1% trifluoroacetic acid, to separate the second post-FPLC fraction into five post-HPLC fractions; and (e) collecting the fourth post-FPLC fraction for further purification. Fluorescence spectroscopy shows that this product is a derivative of trypophan or trypophan-like, and mass spectrometry indicates that it has a molecular weight of about 604 daltons with a minor peak having a molecular weight of about 779 daltons.